These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30957730)

  • 21. The Use of Evidence-Informed Deliberative Processes for Health Benefit Package Design in Kazakhstan.
    Oortwijn W; Surgey G; Novakovic T; Baltussen R; Kosherbayeva L
    Int J Environ Res Public Health; 2022 Sep; 19(18):. PubMed ID: 36141691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three Approaches to Improve a Practical Guide on Evidence-Informed Deliberative Processes for Health Benefit Package Design Comment on "Evidence-Informed Deliberative Processes for Health Benefit Package Design - Part II: A Practical Guide".
    Guzman J
    Int J Health Policy Manag; 2023; 12():7502. PubMed ID: 36086853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic literature review on the implicit factors influencing the HTA deliberative process in Europe.
    Monleón C; Späth HM; Crespo C; Dussart C; Toumi M
    J Mark Access Health Policy; 2022; 10(1):2094047. PubMed ID: 35811835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Evidence-Informed Deliberative Processes - Learning by Doing Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe".
    Culyer AJ
    Int J Health Policy Manag; 2020 Jun; 9(6):263-265. PubMed ID: 32613796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force.
    Oortwijn W; Husereau D; Abelson J; Barasa E; Bayani DD; Santos VC; Culyer A; Facey K; Grainger D; Kieslich K; Ollendorf D; Pichon-Riviere A; Sandman L; Strammiello V; Teerawattananon Y
    Int J Technol Assess Health Care; 2022 Jun; 38(1):e37. PubMed ID: 35656641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force.
    Oortwijn W; Husereau D; Abelson J; Barasa E; Bayani DD; Canuto Santos V; Culyer A; Facey K; Grainger D; Kieslich K; Ollendorf D; Pichon-Riviere A; Sandman L; Strammiello V; Teerawattananon Y
    Value Health; 2022 Jun; 25(6):869-886. PubMed ID: 35667778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Key principles for the improved conduct of health technology assessments for resource allocation decisions.
    Drummond MF; Schwartz JS; Jönsson B; Luce BR; Neumann PJ; Siebert U; Sullivan SD
    Int J Technol Assess Health Care; 2008; 24(3):244-58; discussion 362-8. PubMed ID: 18601792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Community views and perspectives on public engagement in health technology assessment decision making.
    Wortley S; Tong A; Howard K
    Aust Health Rev; 2017 Mar; 41(1):68-74. PubMed ID: 27050156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Defining the Value of Health Technologies in Latin America: Developments in Value Frameworks to Inform the Allocation of Healthcare Resources.
    Pichon-Riviere A; Garcia-Marti S; Oortwijn W; Augustovski F; Sampietro-Colom L
    Int J Technol Assess Health Care; 2019 Jan; 35(1):64-68. PubMed ID: 30938278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HTA and MCDA solely or combined? The case of priority-setting in Colombia.
    Castro HE; Moreno-Mattar O; Rivillas JC
    Cost Eff Resour Alloc; 2018; 16(Suppl 1):47. PubMed ID: 30455606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The link between health technology assessment and decision making for the allocation of health resources in Latin America.
    Pichon-Riviere A; Augustovski F; García Martí S; Alfie V; Sampietro-Colom L
    Int J Technol Assess Health Care; 2020 Apr; 36(2):173-178. PubMed ID: 32312340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implicit factors influencing the HTA deliberative processes in 5 European countries: results from a mixed-methods research.
    Monleón C; Martin-Späth H; Crespo C; Dussart C; Toumi M
    Health Policy Open; 2023 Dec; 5():100109. PubMed ID: 38073709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterogeneous Recommendations for Oncology Products Among Different HTA Systems: A Comparative Assessment.
    Jarosławski S; Hanna E; Dabbous M; Chachoua L; Toumi M
    Recent Results Cancer Res; 2019; 213():39-55. PubMed ID: 30543006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of health technology assessment in coverage decisions on newborn screening.
    Fischer KE; Grosse SD; Rogowski WH
    Int J Technol Assess Health Care; 2011 Oct; 27(4):313-21. PubMed ID: 22004771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Use of Evidence-Informed Deliberative Processes for Health Insurance Benefit Package Revision in Iran.
    Nouhi M; Baltussen R; Razavi SS; Bijlmakers L; Sahraian MA; Goudarzi Z; Farokhian P; Khedmati J; Jahangiri R; Olyaeemanesh A
    Int J Health Policy Manag; 2022 Dec; 11(11):2719-2726. PubMed ID: 35247943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Introducing health technology assessment in Tanzania.
    Surgey G; Chalkidou K; Reuben W; Suleman F; Miot J; Hofman K
    Int J Technol Assess Health Care; 2020 Apr; 36(2):80-86. PubMed ID: 31402790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Moving Towards Accountability for Reasonableness - A Systematic Exploration of the Features of Legitimate Healthcare Coverage Decision-Making Processes Using Rare Diseases and Regenerative Therapies as a Case Study.
    Wagner M; Samaha D; Casciano R; Brougham M; Abrishami P; Petrie C; Avouac B; Mantovani L; Sarría-Santamera A; Kind P; Schlander M; Tringali M
    Int J Health Policy Manag; 2019 Jul; 8(7):424-443. PubMed ID: 31441279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness.
    Baltussen R; Jansen MP; Mikkelsen E; Tromp N; Hontelez J; Bijlmakers L; Van der Wilt GJ
    Int J Health Policy Manag; 2016 Nov; 5(11):615-618. PubMed ID: 27801355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Harnessing Country Experiences for Health Benefit Package Design: Evidence-Informed Deliberative Processes and Experiences From the Joint Learning Network Comment on "Evidence-Informed Deliberative Processes for Health Benefit Package Design - Part II: A Practical Guide".
    Nagpal S; Ahluwalia N; Hashiguchi LO; McGee K; Lutalo M
    Int J Health Policy Manag; 2023; 12():7856. PubMed ID: 38618786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.